TrivarX Limited
MDBIF
Other OTC0.00
USD
- -
- -
ISIN
AU0000300196
Return %
Stock
S&P500
1Y
-89.32
18.21
3Y
-84.15
63.29
5Y
-98.37
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kai Sun
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 647 Beaufort Street Mount Lawley WA Australia 6050
- IPO Date
- Jun 5, 2017
- Website
- trivarx.com
- Similar Companies
- Business
- TrivarX Limited (ASX:TRI; OTC:MDBIF), formerly Medibio Limited, is an Australia-based health technology company that develops AI-driven, scientifically-based devices and algorithms for screening, diagnosis and management of mental health disorders, including depression and anxiety; its lead product, MEB-001, analyzes electrical signals from the brain and heart captured during standard sleep studies to detect depression with over 85% sensitivity, surpassing traditional clinical assessments at 46% accuracy; additional offerings include proprietary spectral analyses of sleep architecture and heart-rate variability biomarkers, a new AI tool to expand patient reach, and ilumen, a corporate wellness platform for stress and mental health monitoring. Founded in 1998 and headquartered in Mount Lawley, Western Australia, with offices in Perth and Minneapolis, Minnesota, USA, the company targets healthcare providers, veterans, corporate clients and global markets, including pilots with Major League Baseball affiliates, Compass Group and partnerships like Northern Michigan University. Recent developments include exercising an option in November 2025 to advance the acquisition of Stabl-Im technology for mental health applications; completing patient recruitment for a US Veterans Affairs trial in October 2025 with positive interim results; securing firm commitments for $2.25 million in March 2025 and earlier placements; launching a US-veteran focused trial with IRB approval and site activation at West LA VA Medical Center; appointing US healthcare executive John Mathias to the board and Dr. Tony Keating as director in 2024-2025; and receiving positive FDA feedback on MEB-001 pre-submissions while reporting 16% revenue growth to $1.03 million in fiscal 2025.